← Back to patent-cliff list
Mitiglinide
Tier C — Watch / tradeMitiglinide
Kissei Pharmaceutical Co., Ltd.
Originator
2004
First approval
-
Expiry (public)
$0.05B ▲
Peak sales
Small molecule
Type
Targets：Potassium channel, VGKCs
Brand：Glinsuna, Glufast
Indications (approved)：Type 2 diabetes
Regional status
US
-
EU
-
China
Approved
2008-09-02
Japan
Approved
2004-01-29
Synthetic routes & intermediates5 routes
Originator routes × 1Optimised (non-patent) × 4Process routes × 0
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
OriginatorRoute 1Steps 5 · Total yield /
MITI-001123-25-1MITI-002100-39-0MITI-00379909-18-5MITI-004884-33-3MITI-0053972-36-9MITI-0061220913-24-5MITI-007671204-00-5API · Mitiglinide
| Code | CAS No. | Intermediate |
|---|---|---|
| MITI-001 | 123-25-1 | diethyl succinate |
| MITI-002 | 100-39-0 | (bromomethyl)benzene |
| MITI-003 | 79909-18-5 | diethyl 2-benzylsuccinate |
| MITI-004 | 884-33-3 | 2-benzylsuccinic acid |
| MITI-005 | 3972-36-9 | (S)-2-benzylsuccinic acid |
| MITI-006 | 1220913-24-5 | (3aR,7aS)-octahydro-1H-isoindole |
| MITI-007 | 671204-00-5 | (S)-2-benzyl-4-((3aR,7aS)-octahydro-2H-isoindol-2-yl)-4-oxobutanoic acid |
OptimisedRoute 2Steps 6 · Total yield /
MITI-001123-25-1MITI-0061220913-24-5MITI-007671204-00-5MITI-008100-52-7MITI-00957367-58-5MITI-0105653-88-3MITI-01146324-06-5MITI-012219712-08-0MITI-0133886-69-9API · Mitiglinide
| Code | CAS No. | Intermediate |
|---|---|---|
| MITI-001 | 123-25-1 | diethyl succinate |
| MITI-006 | 1220913-24-5 | (3aR,7aS)-octahydro-1H-isoindole |
| MITI-007 | 671204-00-5 | (S)-2-benzyl-4-((3aR,7aS)-octahydro-2H-isoindol-2-yl)-4-oxobutanoic acid |
| MITI-008 | 100-52-7Available | benzaldehyde |
| MITI-009 | 57367-58-5 | (Z)-3-(methoxycarbonyl)-4-phenylbut-3-enoic acid |
| MITI-010 | 5653-88-3 | (Z)-2-benzylidenesuccinic acid |
| MITI-011 | 46324-06-5 | (Z)-3-benzylidenedihydrofuran-2,5-dione |
| MITI-012 | 219712-08-0 | 2-((Z)-benzylidene)-4-((3aR,7aS)-octahydro-2H-isoindol-2-yl)-4-oxobutanoic acid |
| MITI-013 | 3886-69-9Available | (R)-1-phenylethan-1-amine |
OptimisedRoute 3Steps 6 · Total yield 16.1 g
MITI-0061220913-24-5MITI-007671204-00-5MITI-014501-52-0MITI-015102029-44-7MITI-016136159-65-4MITI-0175292-43-3MITI-018337518-86-2MITI-0191141895-98-8MITI-0201141896-00-5API · Mitiglinide
| Code | CAS No. | Intermediate |
|---|---|---|
| MITI-006 | 1220913-24-5 | (3aR,7aS)-octahydro-1H-isoindole |
| MITI-007 | 671204-00-5 | (S)-2-benzyl-4-((3aR,7aS)-octahydro-2H-isoindol-2-yl)-4-oxobutanoic acid |
| MITI-014 | 501-52-0 | 3-phenylpropanoic acid |
| MITI-015 | 102029-44-7Available | (R)-4-benzyloxazolidin-2-one |
| MITI-016 | 136159-65-4 | (R)-4-benzyl-3-(3-phenylpropanoyl)oxazolidin-2-one |
| MITI-017 | 5292-43-3 | tert-butyl 2-bromoacetate |
| MITI-018 | 337518-86-2 | tert-butyl (S)-3-benzyl-4-((R)-4-benzyl-2-oxooxazolidin-3-yl)-4-oxobutanoate |
| MITI-019 | 1141895-98-8 | (S)-3-benzyl-4-((R)-4-benzyl-2-oxooxazolidin-3-yl)-4-oxobutanoic acid |
| MITI-020 | 1141896-00-5 | (S)-2-benzyl-1-((R)-4-benzyl-2-oxooxazolidin-3-yl)-4-((3aR,7aS)-octahydro-2H-isoindol-2-yl)butane-1,4-dione |
OptimisedRoute 4Steps 5 · Total yield 296 g
MITI-0217060-39-1MITI-0227326-19-4MITI-0231373511-68-2MITI-024—MITI-025—MITI-026—API · Mitiglinide
| Code | CAS No. | Intermediate |
|---|---|---|
| MITI-021 | 7060-39-1 | (E)-2-amino-3-phenylacrylic acid |
| MITI-022 | 7326-19-4 | (R)-2-hydroxy-3-phenylpropanoic acid |
| MITI-023 | 1373511-68-2 | (R)-3-phenyl-2-(tosyloxy)propanoic acid |
| MITI-024 | - | - |
| MITI-025 | - | 2-chloro-1-((3aR,7aS)-octahydro-2H-isoindol-2-yl)ethan-1-one |
| MITI-026 | - | - |
OptimisedRoute 5Steps 6 · Total yield 0.82 g
MITI-0061220913-24-5MITI-007671204-00-5MITI-0175292-43-3MITI-02794594-90-8MITI-028645-45-4MITI-029127392-81-8MITI-030787635-22-7MITI-031787635-23-8MITI-032787635-24-9API · Mitiglinide
| Code | CAS No. | Intermediate |
|---|---|---|
| MITI-006 | 1220913-24-5 | (3aR,7aS)-octahydro-1H-isoindole |
| MITI-007 | 671204-00-5 | (S)-2-benzyl-4-((3aR,7aS)-octahydro-2H-isoindol-2-yl)-4-oxobutanoic acid |
| MITI-017 | 5292-43-3 | tert-butyl 2-bromoacetate |
| MITI-027 | 94594-90-8 | (3aS,6R)-8,8-dimethylhexahydro-3H-3a,6-methanobenzo[c]isothiazole 2,2-dioxide |
| MITI-028 | 645-45-4 | 3-phenylpropanoyl chloride |
| MITI-029 | 127392-81-8 | 1-((3aS,6R)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-3-phenylpropan-1-one |
| MITI-030 | 787635-22-7 | tert-butyl (3S)-3-benzyl-4-((3aS,6R)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-4-oxobutanoate |
| MITI-031 | 787635-23-8 | (3S)-3-benzyl-4-((3aS,6R)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-4-oxobutanoic acid |
| MITI-032 | 787635-24-9 | (2S)-2-benzyl-1-((3aS,6R)-8,8-dimethyl-2,2-dioxidotetrahydro-3H-3a,6-methanobenzo[c]isothiazol-1(4H)-yl)-4-((3aR,7aS)-octahydro-2H-isoindol-2-yl)butane-1,4-dione |
Frequently asked questions
What are the approved indications of Mitiglinide?
Approved indications include: Type 2 diabetes.
When does the Mitiglinide patent expire?
No public expiry year is available for Mitiglinide yet; this page updates once verified.
How many synthesis routes are recorded for Mitiglinide?
5 synthesis routes are recorded; the shortest is 5 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Mitiglinide intermediates?
3 intermediate CAS of Mitiglinide are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Mitiglinide intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-27